Product Description
Conjugate Light is developing GQ-1001 as a treatment for HER2-Positive advanced solid tumors. These include the following; HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04450732)
Mechanisms of Action: HER2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Conjugate Light
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05575804 |
GRACE | P2 |
Recruiting |
Breast Cancer |
2025-01-01 |
25% |
2024-02-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
ACTRN12620000592943 |
ACTRN12620000592943 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2024-08-29 |
Treatments |
|
CTR20211739 |
CTR20211739 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Treatments |